司美格鲁肽联合短期胰岛素强化治疗初诊2型糖尿病并肥胖症的临床效果  

Clinical effect of semaglutide combined with short-term intensive insulin therapy on newly diagnosed type 2 diabetes mellitus complicated with obesity

作　　者：叶晓晓 杨清敏[1] YE Xiaoxiao;YANG Qingmin(Endocrinology Department,Henan Hongli Hospital,Xinxiang 453400,China)

机构地区：[1]河南宏力医院内分泌科,河南新乡453400

出　　处：《临床医学研究与实践》2025年第5期49-52,共4页Clinical Research and Practice

摘　　要：目的探讨司美格鲁肽联合短期胰岛素强化治疗初诊2型糖尿病并肥胖症的临床效果。方法选取2021年6月至2023年1月我院收治的70例初诊2型糖尿病并肥胖症患者作为研究对象,以双盲法随机将其分为对照组(n=35)和观察组(n=35)。对照组患者予以胰岛素泵治疗,观察组患者在对照组的基础上联合司美格鲁肽治疗。比较两组的临床疗效、血糖水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)水平及糖化血红蛋白(HbA1c)]、血脂水平[甘油三酯(TG)、总胆固醇(TC)]与体重指数(BMI)、不良反应发生情况。结果观察组的治疗总有效率为88.57%,显著高于对照组的68.57%,差异具有统计学意义(P<0.05)。治疗后,两组的FPG、2 h PG水平及HbA1c均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的TG、TC水平及BMI降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论司美格鲁肽联合短期胰岛素强化治疗初诊2型糖尿病并肥胖症的效果确切,不仅有助于控制患者血糖水平,还能调节血脂、减轻体重,且不良反应少,值得临床推广及应用。Objective To investigate the clinical effect of semaglutide combined with short-term intensive insulin therapy on newly diagnosed type 2 diabetes mellitus complicated with obesity.Methods A total of 70 patients with newly diagnosed type 2 diabetes mellitus complicated with obesity admitted in our hospital from June 2021 to January 2023 were selected as the research objects.The patients were randomly divided into control group(n=35)and observation group(n=35)by double-blind method.The patients in the control group were treated with insulin pump,and the patients in the observation group were treated with semaglutide on the basis of the control group.The clinical efficacy,blood glucose levels[fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG)and glycosylated hemoglobin(HbA1c)],blood lipid levels[triglyceride(TG),total cholesterol(TC)],body mass index(BMI)and adverse reactions were compared between the two groups.Results The total effective rate of treatment was 88.57%in the observation group,which was significantly higher than 68.57%in the control group,and the difference was statistically significant(P<0.05).After treatment,the FPG,2 h PG levels and HbA1c in the two groups decreased,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).After treatment,the TG,TC levels and BMI in the two groups decreased,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Semaglutide combined with short-term intensive insulin therapy for newly diagnosed type 2 diabetes complicated with obesity has exact effect.It not only helps to control the blood glucose level of patients,but also significantly regulates blood lipids and reduces body weight,and has fewer adverse reactions,which is worthy of clinical promotion and application.

关 键 词：2型糖尿病 肥胖症 司美格鲁肽 胰岛素 血脂 

分 类 号：R587.1[医药卫生—内分泌]